Tech Company Financing Transactions
Kinex Pharmaceuticals Funding Round
Kinex Pharmaceuticals, based in Buffalo, secured $40 million from private investors.
Transaction Overview
Company Name
Announced On
3/6/2014
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from this round, coupled with cash on hand, will be used to fund the completion of the commercialization of its oral form of paclitaxel (Oraxol) and irinotecan (Oratecan) in select markets outside of the United States. In addition, the proceeds will fund mid-stage clinical trials in the United States of four of eight Kinex drug candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
701 Ellicott St.
Buffalo, NY 14203
USA
Buffalo, NY 14203
USA
Phone
Website
Email Address
Overview
Kinex is a specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Johnson Lau
Chief Medical Officer
Rudolf Kwan
Chief Operating Officer
Flint Besecker
Chief Scientific Officer
David Hangauer
Browse more venture capital transactions:
Prev: 3/6/2014: iCardiac Technologies venture capital transaction
Next: 3/6/2014: Canary venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs